Skip to main content
Clinical Trials/IRCT20110512006463N3
IRCT20110512006463N3
Completed
Phase 3

A comparison of complication & major cardiovascular events of bolus eptifibatide versus bolus plus infusion of eptifibatide in Primary PCI in patients with acute ST-elevation myocardial infarction

Deputy of research and technology of Alborz University of Medical Sciences0 sites163 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Deputy of research and technology of Alborz University of Medical Sciences
Enrollment
163
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Deputy of research and technology of Alborz University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Patients with symptoms of ischemic heart attack that last no longer than 12 hours with 1 mm ST elevation in at least 2 limb leads or 2 mm ST elevation in at least 2 precordial leads who are candidates for Primary PCI intervention.

Exclusion Criteria

  • Not acceptance of informed consent
  • History of sensitivity to eptifibatide, heparin or aspirin
  • Recent treatment with warfarin (INR\>2\), fibrinolythics or other IIbIIIa inhibitors
  • Platelet \<100000/mcL
  • Known bleeding disorder
  • History of ischemic cerebrovascular accident in previous 30 days
  • History of hemorrhagic cerebrovascular accident
  • Abnormal bleeding in recent 30 days.
  • Major surgery in previous 6 weeks
  • Renal failure with dependency to hemodialysis

Outcomes

Primary Outcomes

Not specified

Similar Trials